Lauren MBA - ImmunoGen Senior Officer
Executive
Lauren MBA is Senior Officer of ImmunoGen
| Age | 45 |
| Phone | 781 895 0600 |
| Web | https://www.immunogen.com |
ImmunoGen Management Efficiency
The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.ImmunoGen currently holds 15.24 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. ImmunoGen has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ImmunoGen's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Adam Waldman | TG Therapeutics | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| John Schembri | Akero Therapeutics | 63 | |
| Spencer JD | PDS Biotechnology Corp | 55 | |
| Thomas Ross | Akero Therapeutics | N/A | |
| Mark Winderlich | Hookipa Pharma | 39 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| Biren Shah | Elevation Oncology | N/A | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Catriona Yale | Akero Therapeutics | 53 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Mark MA | Axsome Therapeutics | 42 | |
| Patrick Lamy | Akero Therapeutics | 52 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 |
ImmunoGen Leadership Team
Elected by the shareholders, the ImmunoGen's board of directors comprises two types of representatives: ImmunoGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoGen. The board's role is to monitor ImmunoGen's management team and ensure that shareholders' interests are well served. ImmunoGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, VP Officer | ||
| Susan Altschuller, VP CFO | ||
| MMSc MD, VP Officer | ||
| Lauren MBA, Senior Officer | ||
| Renee Lentini, VP Officer | ||
| Stacy Coen, Sr Officer | ||
| Audrey Bergan, Senior Officer | ||
| Courtney OKonek, Senior Relations | ||
| Isabel Kalofonos, Senior Officer | ||
| Anabel Chan, Head Relations | ||
| FACP MD, VP Affairs | ||
| Mark Enyedy, President CEO, Director | ||
| Theresa Wingrove, Vice President - Regulatory Affairs and Quality | ||
| Stacy MBA, Senior Officer |
ImmunoGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmunoGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X |
Pair Trading with ImmunoGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Jabil Circuit could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jabil Circuit when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jabil Circuit - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jabil Circuit to buy it.
The correlation of Jabil Circuit is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jabil Circuit moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jabil Circuit moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jabil Circuit can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |